Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype

Cancer Letters

Volumn 157, Issue 1, 2000, Pages 23-30

  Kim, Mi Sung ^a   Son, Mi Won ^b   Kim, Won Bae ^b   In Park, Young ^c   Moon, Aree ^a  

^a Duksung Women's University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

^c Korea University   (South Korea)

Author keywords

Apicidin; Detransformation; H ras; Histone deacetylase inhibitor; Invasion; Matrix metalloproteinase

Indexed keywords

ANTINEOPLASTIC AGENT; APICIDIN; ENZYME INHIBITOR; GELATINASE A; GELATINASE B; HISTONE DEACETYLASE; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST EPITHELIUM; CELL INVASION; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; METASTASIS; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL;

BREAST; CELL DIVISION; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; EPITHELIAL CELLS; GENES, RAS; GROWTH INHIBITORS; HISTONE DEACETYLASES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PEPTIDES, CYCLIC; PHENOTYPE;

EID: 0034739319     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00465-1     Document Type: Article

References (25)

1. Darkin-Rattray S., Gurnett A.M., Myres R.W., Dulski P.M., Crumely K.M., Allocco J.J., Cannova C., Meinke P.T., Colletti S.L., Bednarek M.A., Singh S.B., Goetz M.A., Dombrowski A.W., Polishook J.D., Schimatz D.M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA. 93:1996;13143-13147.
2. Itazaki H., Nagashima K., Sugita K., Yoshida H., Kawamura Y., Yasuda Y., Matsumoto K., Ishii K., Uotani N., Nakai H., Terui A., Yoshimatsu S., Ikenishi Y., Nakagawa Y. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J. Antibiot. 43:1990;1524-1532.
3. Park J.-S., Lee K.-R., Kim J.-C., Lim S.-H., Seo J.-A., Lee Y.-W. A hemorragic factor (apicidin) produced by a toxic Fusarium isolates from soybean seeds. Appl. Environ. Microbiol. 65:1999;126-130.
4. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 389:1997;349-352.
5. Yoshida H., Sugita K. A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells. Jpn. J. Cancer Res. 83:1992;324-328.
6. Sugita K., Koizumi K., Yoshida H. Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. Cancer Res. 52:1992;168-172.
7. Kwon H.J., Owa T., Hassig C.A., Shimada J., Schreiber S.L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA. 95:1998;3356-3361.
8. Oikawa T., Onozawa C., Inose M., Sasaki M. Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo. Biol. Pharm. Bull. 18:1995;1305-1307.
9. Kim Y.B., Lee K.-H., Sugita K., Yoshida M., Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene. 18:1999;2461-2470.
10. Arts J., Lansink M., Grimbergen J., Toet K.H., Kooistra T. Stimulation of tissue type plaminogen activator gene expression by sodium butyrate and TSA in human endothelial cells involves histone acetylation. Biochem. J. 310:1995;171-176.
11. Vicente M., Belinda E., Graeme P.Y., Robert J., Sarah A., Peter D.Z. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (Inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 57:1997;3697-3707.
12. Liotta L.A. Tumor invasion and metastasis - role of the extracellular matrix. Cancer Res. 46:1986;1-7.
13. Tryggvason K. Type IV collagenase in invasive tumors. Breast Cancer Res. 24:1993;209-218.
14. Moon A., Kim M.-S., Kim T.-G., Kim S.-H., Kim H.E., Chen Y.Q., Kim Choi H.-R. H-ras, but N-ras, induces and invasive phenotype in human breast ephedial calls: A role for MMP-2 in the H-ras-indused unvasive phenotype. Int. J. Cancer. 85:2000;176-181.
15. Bernhard E.J., Gruber S.B., Muschel R.J. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA. 91:1994;4293-4297.
16. Soule H., Maloney T.M., Wolman S.R., Peterspm W.D., Brenz R., McGrath C.M., Russo J., Pauley R.J., Jones R.F., Brooks S.C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50:1990;6075-6086.
17. Inoue A., Fujimoto D. Histone deacetylase from calf thymus. Biochim. Biophys. Acta. 220:1970;307-316.
18. Peter E.M., Reeves R., Davie J.R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 14:1978;105-113.
19. Wahrman M.Z., Gagnier S.E., Kobrin D.R., Higgins P.J., Augenlicht L.H. Cellular and molecular changes in 3T3 cells transformed spontaneously or by DNA transfection. Tumor Biol. 6:1985;41-56.
20. Hoshikawa Y., Kwon H.L., Yoshida M., Horinouchi S., Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp. Cell Res. 214:1994;189-197.
21. Kijima M., Yoshida M., Sugita K., Horinouchi S., Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 265:(30):1993;22429-22435.
22. Azzam H., Arland G., Lippman M., Thompson E. Association of MMP-2 activation potential with metastatic progression in human breast-cancer cell lines independent of MMP-2 production. J. Nat. Cancer Inst. 85:1993;1758-1764.
23. Barbacid M. ras genes. Annu. Rev. Biochem. 56:1987;779-827.
24. Sugita K., Yoshida H., Matsumoto M., Matsutani S. A novel compound, depudecin, induces production of transformation to the flat phenotype of NIH3T3 cells transformed by ras-oncogene. Biochem. Biophys. Res. Commun. 182:1992;379-387.
25. Sonoda H., Nishida K., Yoshida T., Ohtani M., Sugita K. Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD. Oncogene. 13:1996;143-146.